NVTR - Axonics Modulation Technologies Proposes Terms For $100 Million IPO
Quick Take
Axonics Modulation Technologies (AXNX) intends to raise $100 million from the sale of its common stock in an IPO, per an amended registration statement.
The company is developing a sacral neuromodulation device to treat a number of urinary tract conditions.
AXNX is nearing U.S. approval, but the proposed IPO valuation isn't cheap and the firm faces significant, entrenched competition.
Company & Technology
Irvine, California-based Axonics Modulation was founded in 2013 to develop and market a minimally invasive rechargeable SNM (r-SNM) system for patients with overactive bladder [OAB], fecal incontinence [FI],